Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
about
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Role of Peroxisome Proliferator-Activated Receptors in Inflammation ControlBreaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticlesInhibition of Carrageenan-Induced Cutaneous Inflammation by PPAR Agonists Is Dependent on Hepatocyte-Specific Retinoid X ReceptorAlphaThe non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesDown-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes.Minireview: Challenges and opportunities in development of PPAR agonistsPPARγ agonist through the terminal differentiation phase is essential for adipogenic differentiation of fetal ovine preadipocytesA combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonistsSpecific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonistsMulti-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats.Differentiating members of the thiazolidinedione class: a focus on efficacy.Novel insulin sensitizers: pharmacogenomic aspects.Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulinPharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Effects of thiazolidinediones on bone loss and fracture.Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.PPARgamma: a novel molecular target in lung disease.The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.Topical peroxisome proliferator activated receptor activators accelerate postnatal stratum corneum acidification.Tributyltin differentially promotes development of a phenotypically distinct adipocyteInsulin-sensitising agents: beyond thiazolidinediones.Should We Use PPAR Agonists to Reduce Cardiovascular Risk?PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Treating insulin resistance: future prospects.Selective modulation of promoter recruitment and transcriptional activity of PPARgamma.Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinedionesThe possible role of peroxisome proliferator-activated receptor gamma in heart failure.PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal.Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophagesAdipocyte reporter assays: application for identification of anti-inflammatory and antioxidant properties of mangosteen xanthones.PPARgamma as a potential therapeutic target in pulmonary hypertension.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.Engineering and optimization of an allosteric biosensor protein for peroxisome proliferator-activated receptor γ ligands.Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinedionesTroglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.
P2860
Q24564203-87AAC015-5256-4BEC-8873-37E810E5F022Q24796541-C4577300-2D62-46AB-92B3-D359CC82F691Q26830366-3F962925-199D-4CCC-9FE6-32CC9BA332A8Q28218456-E356AE9E-E00B-47F0-A2EE-BDF34597EC25Q28238709-0636B097-362C-42EA-9F85-7BA4E37CE7B9Q31514175-B85B18AA-842C-45FF-8705-B324885F152AQ33631921-0C853115-9524-4B6C-9A0E-5D3B5880BFE9Q33634827-3BEF7BFB-ED84-43E2-8985-3562739F0897Q33772720-DD81E142-8172-41BB-97AC-B0AFC1A2AC3DQ33809071-3D80EF34-6758-4687-BB3B-3446028538ACQ34011043-68B3F32B-939E-4CAF-8479-F0B51589DA65Q34501727-CB8A9E03-0E66-4ADD-BED6-20F81AAA779BQ34580989-E7E68781-A867-4C7D-AA52-F65482F8076DQ34609164-2388645C-7DA0-4B46-B041-9966AAAA8C75Q34620604-9C086145-B0FE-4447-8164-6586FF51A1AFQ34628781-CF2805D0-001D-4F10-9760-822256DAC21DQ34701705-2F920D40-15B1-44A2-9A4C-26023797A75DQ35207615-B0C506B1-C8EC-442C-83E6-C777959D3E98Q35805954-AA5DD416-DA2B-4091-B0D7-F3BD7979658EQ35925357-DE31CA97-E919-4A78-AD99-8944704F6526Q35925797-5F31C902-B881-4C81-A6DE-DF57754A6A30Q35994887-52CDDCB9-10F0-496A-8932-A279B768CD41Q36001649-98B735F1-3572-4B04-80C7-E86CA9258F5CQ36179691-722F8D41-EAD9-4198-BFA9-043B6D1E9206Q36446970-CE3671BE-C77D-4CCA-A0E8-4ED029A68FAFQ36787677-EF8AE3BC-A3C4-429D-A02C-DC5483FC288AQ36806514-7557DDC4-D166-420D-8FC0-EED1818428F6Q36979694-7ACD4CEC-7C9F-4614-B016-BD5999C9DE5BQ37242352-D55074FE-85FB-4B7C-805E-E27CC417AE9DQ37271252-3306C2AD-7449-4359-AA0B-376C41FFF63AQ37277818-29120045-652E-4723-B421-4155245AA749Q37360041-CCB9860A-091A-45EE-B101-8890F2B2057AQ37395127-0A96C6A6-2CE9-412E-ABF8-A6789C7D0398Q37624519-4ECF47B0-24C2-4EE5-A65D-3BFEDD7B7CA3Q37689190-A26FC060-0C0E-414F-B1AE-8A10A526930DQ37724195-E7638E19-287C-4FD3-8F42-390119B20CB2Q37997004-4EADF7AC-6863-484E-8798-1CE2FA8F8C2AQ39085753-6E308A82-C976-4A97-AEBC-DF349363DC7EQ39860554-5CA73C3D-EF8B-4CBF-B45F-67F934A38091Q40215655-E5FFD235-62D6-41AC-8875-6E54946BA154
P2860
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Differential activation of per ...... roglitazone and rosiglitazone.
@ast
Differential activation of per ...... roglitazone and rosiglitazone.
@en
type
label
Differential activation of per ...... roglitazone and rosiglitazone.
@ast
Differential activation of per ...... roglitazone and rosiglitazone.
@en
prefLabel
Differential activation of per ...... roglitazone and rosiglitazone.
@ast
Differential activation of per ...... roglitazone and rosiglitazone.
@en
P2093
P1433
P1476
Differential activation of per ...... roglitazone and rosiglitazone.
@en
P2093
Frankowski CL
Vanbogelen R
P304
P356
10.2337/DIABETES.49.4.539
P407
P577
2000-04-01T00:00:00Z